Frazier capitalizes on Calistoga, recruits former CEO Gallagher to the VC firm
This article was originally published in Scrip
Executive Summary
Two and a half years after Calistoga Pharmaceuticals was acquired by Gilead Sciences for up to $600m, Frazier Healthcare finally lured Calistoga's former CEO Carol Gallagher to help the venture capital firm replicate its successful investment in the cancer drug developer.